EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis

Tina Vilsbøll, Maciej T Malecki, Palash Sharma, Vivian T Thieu iD, Krishna Karthik Chivukula, Jacek Kiljanski iD

Diabetes, Obesity and Metabolism · 2025-10 · 27 (10) · 5498-5505

DOI: 10.1111/dom.16592 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 31.07.2025. Verfasst von Tina Vilsbøll und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research, Steno Diabetes Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Tirzepatide. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Tirzepatide is a dual glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist for type 2 diabetes, chronic weight management and obstructive sleep apnoea (in the US). To assess the contribution of weight loss (WL) to the observed glycaemic effect, we performed mediation analysis of three randomized, controlled, parallel, 4‐arm SURPASS(S)‐trials; 1, 2 and 5, for a total of 2831 participants. Materials and Methods WL dependent (WL‐D) and WL independent (WL‐IND) effects on comparator‐adjusted glycated haemoglobin A1c (HbA1c) reduction at Week 40 were estimated using mediation analysis, adjusted for baseline HbA1c and study‐specific stratification factors.

Results

The difference in mean HbA1c change from baseline at 40 weeks (total effect) between tirzepatide and the placebo group ranged from −20.0 to −14.6 mmol/mol, and that between tirzepatide and semaglutide (1 mg) ranged from −5.1 to −1.9 mmol/mol. In the placebo‐controlled trials, 12%–27% of the difference in HbA1c change between tirzepatide dose arms and placebo was estimated as being mediated through WL when given as monotherapy (S1), and 25%–45% when on the background of insulin with or without metformin (S5). Compared with semaglutide, 54%–71% of the difference in HbA1c change between tirzepatide and semaglutide was estimated as being WL‐D.

Conclusion

The tirzepatide‐induced HbA1c reductions from baseline, compared with placebo or semaglutide, were mediated through both WL‐D and WL‐IND effects. Estimated contributions of WL to the difference in glycaemic efficacy varied and were highest when tirzepatide was compared with semaglutide and less pronounced when compared with placebo. These results help to understand that other factors beyond weight reduction contribute to HbA1c reduction with tirzepatide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glycated HemoglobinHypoglycemic AgentsTirzepatideWeight LossAgedFemaleHumansMaleMiddle AgedBlood GlucoseGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesTreatment OutcomeRandomized Controlled Trials as TopicClinical Trials, Phase III as TopicGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

HbA1cSURPASS studiesmediation analysistirzepatideweight lossweight‐loss dependent effectsweight‐loss independent effects

Substanzen

Blood GlucoseGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsTirzepatideGlucagon-Like Peptide 1Semaglutidehemoglobin A1c protein, human

Autor:innen und Institutionen

  • Clinical Research, Steno Diabetes Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID-Profile: Vivian T Thieu, Jacek Kiljanski

Förderung

  • Eli Lilly and Company

Zitieren

APA

Vilsbøll, T., Malecki, M. T., Sharma, P., Thieu, V. T., Chivukula, K. K., & Kiljanski, J. (2025). HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis. Diabetes, Obesity and Metabolism, 27(10), 5498-5505. https://doi.org/10.1111/dom.16592

Vancouver

Vilsbøll T, Malecki MT, Sharma P, Thieu VT, Chivukula KK, Kiljanski J. HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis. Diabetes, Obesity and Metabolism. 2025;27(10):5498-5505. doi:10.1111/dom.16592

BibTeX
@article{Vilsbll2025,
  author = {Vilsbøll, Tina and Malecki, Maciej T and Sharma, Palash and Thieu, Vivian T and Chivukula, Krishna Karthik and Kiljanski, Jacek},
  title = {HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {10},
  pages = {5498--5505},
  doi = {10.1111/dom.16592}
}
Kostenlos starten →